- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01488630
Substance Treatment and HIV Testing and Referral System (STaRS)
Substance Treatment Referral System
The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs. An easy to use, time-efficient referral system is needed to address this problem. The Substance Treatment Referral Systems (STaRS), a computer assisted screening and referral system, was developed to meet this need.
STaRS Phase I demonstrated the feasibility of STaRS to meet this need. All aims and evaluation goals of the Phase I study were met or exceeded. The purpose of the Phase II research is to demonstrate the clinical utility and commercial viability of STaRS.
Specific Aims of Phase II are:
- Integrate STaRS with the Epic electronic health record used in the Cooper Health System in Camden, N.J.
- Document STaRS' effectiveness in (a) increasing the number of referrals provided for substance abuse treatment and HIV screening, and (b) increasing the proportion of patients that initiate specialty treatment.
- Evaluate clinician acceptance and impact upon revenue generation.
The research will be conducted at Cooper Family Medicine (CFM) department of Cooper University Hospital in New Jersey. We will determine the rate of referrals and treatment initiation for 3,500 adult patients treated during treatment as usual (the time before STaRS is implemented at CFM) as well as 3,500 adult patients treated after the introduction of STaRS. Patients will be asked about the referral initiation process, and CFM healthcare providers will be asked to evaluate the system from a clinical and administrative prospective. Finally, billing records will be reviewed during the STaRS implementation to determine whether STaRS impacted revenue for the practices.
Aperçu de l'étude
Description détaillée
STaRS is a computer assisted screening and referral system for problem substance use, designed for use in medical settings. The primary function of STaRS is to facilitate physician referrals for tobacco, alcohol, other drugs, and HIV screening, tailored to the patient's condition and circumstances (e.g., zip code and insurance).
A prototype of STaRS was developed and found to be feasible in medical settings in Phase I. Phase II research will demonstrate clinical utility and commercial viability of the system in a medical setting (e.g., Cooper University Hospital Family Medicine practices). Prior to beginning the Phase II research, focus groups were conducted to refine changes to the STaRS software. These focus groups consisted of healthcare providers from Cooper Family Medicine (CFM) practices.
The Phase II research will be conducted in several parts, described in the following sub-studies, conducted simultaneously:
- Referral Sub-Study. To determine the impact of STaRS on the rate of referral for substance abuse treatment and HIV screening, 7,000 adult patients' charts will be reviewed (3,500 patients seen prior to STaRs implementation and 3,500 patients seen after STaRS implementation).
- Treatment Initiation Sub-Study. To test the effectiveness of STaRS on treatment initiation, 140 patients who receive referrals during the STaRS implementation will be telephoned by research staff and invited to participate in this sub-study to document treatment initiation. Treatment initiation refers to whether the patient has made contact or scheduled an appointment with the referral provider.
- Billing and Revenue Generation Sub-Study. Seven thousand medical records will be reviewed for the referral study (described above). Patients who were given referrals for substance use and HIV screening will have their billing records reviewed by the Cooper Research Assistant (RA). The goal is to determine the amount billed for the session in which the referral was made and the amount paid by the insurer (or Medicaid, Medicare). This data will be used to determine the effectiveness of STaRS to increase revenues for the practices.
- Provider Evaluation of STaRS Sub-Study. At the conclusion of the study, focus groups will be conducted with the CFM healthcare providers. The focus groups will have 3 goals: Rating the STaRS system on ease of use and clinical utility; soliciting suggestions regarding enhancements to STaRS and procedures to implementation and training; and identifying any factors that may have influenced the providers to screen or refer patients.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08102
- Cooper Family Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- All English-speaking adult patients (>= 18 years old) who received a referral for substance abuse treatment or HIV/AIDS screening from Cooper Family Medicine practices during the study period, and who can be reached at a home telephone or have a monthly cell phone plan.
Exclusion Criteria:
- Patients < 18 years old and patients with poor English comprehension, or who do not have reliable telephone access (i.e., no phone access or buys minutes for a "disposable" cell phone)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Dépistage
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: Treatment as Usual
Chart review only.
|
|
Expérimental: STaRS
Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
|
The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Referral Rates for Substance Abuse Treatment and HIV Testing
Délai: Completed after 3500 pre-STaRS charts and 3500 STaRS intervention charts are reviewed, over a period of one year
|
A total of 7000 electronic health records ( referred to as "charts") will be reviewed for referral rates.
Those charts include 3500 pre-STaRS charts (treatment as usual arm) and 3500 STaRS charts (intervention arm)
|
Completed after 3500 pre-STaRS charts and 3500 STaRS intervention charts are reviewed, over a period of one year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Treatment Initiation
Délai: 70 pre-STarS patients and 70 STaRS patients are enrolled, over a period of six months
|
7000 charts will be reviewed, 140 patients who received referrals for substance abuse and/or HIV testing will be enrolled in the treatment initiation study (70 with referrals from pre-STaRS charts and 70 with referrals from STaRS intervention charts.
|
70 pre-STarS patients and 70 STaRS patients are enrolled, over a period of six months
|
Billing Revenue
Délai: 7000 charts reviewed, over a period of one year
|
A total of 7000 electronic health records will be reviewed for referral rates (3500 pre-STaRS, 3500 STaRS intervention).
Charts of patients who received referrals will be further examined to obtain billing information.
This will help determine the impact that STaRS has on increasing revenues to the CFM practices.
|
7000 charts reviewed, over a period of one year
|
Provider Satisfaction
Délai: Last month of the study, November 2012
|
Focus groups will be conducted with healthcare providers who used the STaRS to make referrals.
Data collected at focus groups will be used to improve future versions of STaRS.
|
Last month of the study, November 2012
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Grant Grissom, PhD, Polaris Health Directions
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- N44DA-10-5543
- STaRS (Identificateur de registre: STaRS)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Abus de substance
-
University of BirminghamNewcastle University; National Institute for Health Research, United Kingdom; University of York et autres collaborateursInconnueAbus d'alcool | Abus de drogues
-
Children's Mercy Hospital Kansas CityEunice Kennedy Shriver National Institute of Child Health and Human Development... et autres collaborateursComplétéComportement des adolescents | La violence conjugale | Département d'urgence | Abus physique | Abus mental | Abus verbal | Abus Domestique | CŒURÉtats-Unis
-
University of ReginaSaskatchewan Health Research Foundation; Saskatchewan Centre for Patient-Oriented... et autres collaborateursComplété
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)ComplétéAbus d'AODÉtats-Unis
-
University of ReginaSaskatchewan Health Research Foundation; Saskatchewan Centre for Patient-Oriented...RecrutementAbus d'alcoolCanada
-
Capital Medical UniversityRecrutement
-
Centers for Disease Control and PreventionThe University of Texas Health Science Center, Houston; University of South... et autres collaborateursComplété
-
Stuart WillickSports Medicine Research and Testing Laboratory; Partnership for Clean CompetitionComplétéAbus de drogues sportives | Abus de stéroïdes ou d'hormonesÉtats-Unis
-
Yale UniversityPatient-Centered Outcomes Research InstituteComplété
-
Aveiro UniversityFundação para a Ciência e a TecnologiaComplété
Essais cliniques sur STaRS
-
University of California, San FranciscoSan Francisco Department of Public Health; San Francisco General Hospital; Sonoma...ComplétéDiabète sucré de type 2 | Diabète sucré gestationnelÉtats-Unis
-
Astria Therapeutics, Inc.ComplétéAngiœdème héréditaireÉtats-Unis
-
University of WashingtonAlzheimer's AssociationRecrutementDémence | Maladie d'AlzheimerÉtats-Unis
-
University of WashingtonNational Institute on Aging (NIA); Kaiser PermanenteComplétéSymptômes comportementaux | Démence | Maladie d'Alzheimer | Fardeau des soignantsÉtats-Unis
-
Women's College HospitalUnity Health Toronto; North York General Hospital; William Osler Health System; St. Joseph's Care Group et autres collaborateursComplété
-
Ethicon Endo-Surgery (Europe) GmbHAysgarth Statistics; Physicians World GmbHComplétéIntussusception | Obstruction de la sortie gastrique | Rectocèle | AnismeRoyaume-Uni, France, Italie
-
University Hospital Inselspital, BerneComplétéSyndrome de douleur pelvienne chroniqueSuisse
-
Astria Therapeutics, Inc.RecrutementAngiœdème héréditaireÉtats-Unis, Royaume-Uni, Canada, Allemagne, Bulgarie, Tchéquie
-
Peking UniversityPas encore de recrutement
-
Hacettepe UniversityComplétéDystrophie musculaire de Duchenne | Difficulté de déambulation | Trouble de la marche, neurologiqueTurquie